Ozempic approved in Canada to slow kidney decline, prevent cardiovascular disease
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes.Between 30...
cardiovascular
Health Canada Approves Novo’s Ozempic To Reduce Risk Of Kidney Function Decline, Cardiovascular Death
The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1...
Evaluating the digital health technology landscape in sub-Saharan Africa and its implications for cardiovascular health
Songwe, V. The Role of Digitalization in the Decade of Action for Africa. United Nations Trade and Development News page....
Naturally derived nanoparticles show promise against cardiovascular and kidney disease
Graphical abstract. Credit: Biomaterials (2025). DOI: 10.1016/j.biomaterials.2025.123296 Cardiovascular disease and kidney disease are two of the most urgent issues in...
New Nanoparticle Weapon in the Fight Against Cardiovascular and Kidney Disease – USC Viterbi
Cardiovascular disease is the leading cause of death in the United States. Image/Pexels Cardiovascular disease and kidney disease are two...
Association of chronic kidney disease and cardiovascular disease risk with all-cause mortality: an interaction, joint and mediation analysis in Chinese adults | BMC Public Health
Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet (London England). 2017;389(10075):1238–52.Article PubMed Google Scholar GBDCKDC. Global,...
